All the top level comments are basking in the irony of it, which is fair enough. But I think this changes the Deepseek narrative a bit. If they just benefited from repurposing OpenAI data, that's different than having achieved an engineering breakthrough, which may suggest OpenAI's results were hard earned after all.
It’s the same problem with pharmaceuticals and generics. It’s great when the price of drugs is low, but without perverse financial incentives no company is going to burn billions of dollars in a risky search for new medicines.